论文部分内容阅读
目的探讨无症状高尿酸血症与陈旧性心肌梗死患者预后的关系。方法顺序收集陈旧性心肌梗死患者81例,分为陈旧性心肌梗死组(OMI组)与陈旧性心肌梗死伴无症状高尿酸血症组(OMI伴无症状HUA组),平均随访(16.09±5.06)个月。通过Kaplan-Meier生存曲线及COX回归,分析无症状高尿酸血症与陈旧性心肌梗死患者预后的关系。结果 (1)随访期间共发生心血管终点事件29例,发生率为35.8%。(2)OMI组与OMI伴无症状HUA组比较左室射血分数、GFR差异具有统计学意义。(3)经Kaplan-Meier生存曲线分析示:OMI伴无症状HUA组心血管终点事件发生率明显高于OMI组。(4)COX回归分析显示:COX回归单因素分析显示,以心血管事件为终点时,风险比例(HR)为2.36(95%CI 1.12~5.01,P<0.05),多因素COX回归分析调整年龄、吸烟、高血压、糖尿病等后,风险比例(HR)为2.50(95%CI 0.18~0.89,P<0.05)。结论无症状高尿酸血症与陈旧性心肌梗死患者预后密切相关,无症状高尿酸血症是预测OMI患者心血管终点事件的危险因素。
Objective To investigate the relationship between asymptomatic hyperuricemia and the prognosis of patients with old myocardial infarction. Methods Eighty-one patients with old myocardial infarction were collected and divided into two groups: old myocardial infarction group (OMI group) and old myocardial infarction group with asymptomatic hyperuricemia group (OMI group with asymptomatic HUA group), mean follow-up (16.09 ± 5.06 ) Months. Kaplan-Meier survival curves and COX regression analysis of the relationship between asymptomatic hyperuricemia and the prognosis of patients with old myocardial infarction. Results (1) A total of 29 cardiovascular events occurred during follow-up, the incidence was 35.8%. (2) Compared with OMI group and OMI group with asymptomatic HUA group, left ventricular ejection fraction and GFR had statistical significance. (3) The Kaplan-Meier survival curve analysis showed that the incidence of cardiovascular end point events in OMI with asymptomatic HUA group was significantly higher than that in OMI group. (4) COX regression analysis showed that the univariate analysis of COX regression showed that the risk ratio (HR) was 2.36 (95% CI 1.12-5.01, P <0.05) at the end of cardiovascular events. Multivariate Cox regression analysis adjusted the age , Smoking, hypertension, diabetes, etc. The risk ratio (HR) was 2.50 (95% CI 0.18-0.89, P <0.05). Conclusions Asymptomatic hyperuricemia is closely related to the prognosis of patients with old myocardial infarction. Asymptomatic hyperuricemia is a risk factor for predicting cardiovascular end point events in OMI patients.